Estimation of fetal Thymidine Kinase activity in primary tumors could be a useful parameter in the assessment of early relapses in patients with breast cancer. In a group of 39 women followed up for 42 months, the percentage of early relapses and their frequency was significantly higher in patients whose tumors had a high level of enzyme activity than in others.